Stays on list!
$EyePoint Pharmaceuticals (EYPT.US)$ Im looking for a pullback or to see where it goes? Its Q3 EPS was almost a 30 cents PS beat over expected. And thier pipeline is going to have some developments. Clinical trials approach key data events with top-line Phase 2 DAVIO 2 trial results anticipated in early December, and PAVIA results in Q2 of next year. And so far the data is promising! Not to mention others advancing through trials! Now that $Outlook Therapeutics (OTLK.US)$ got a CRL from FDA. I believe that brings new interest from people looking for a effective WET AMD drug to EYPT? This is JMO. But another reason im bullish here!
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
HutchingsNyamom : their pipeline will never develop... they have one thing in it that will never pass and they know it